Login to Your Account

ViroPharma Sinks After FDA Denies Vancocin Exclusivity

By Marie Powers
Staff Writer

Wednesday, April 11, 2012
Shares of ViroPharma Inc. were rocked Tuesday after the FDA informed the company that the supplemental new drug application (sNDA) for its antibiotic Vancocin (vancomycin hydrochloride), approved in December 2011, would not qualify for three additional years of exclusivity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription